-
公开(公告)号：US20240262884A1
公开(公告)日：2024-08-08
申请号：US18625702
申请日：2024-04-03
IPC分类号： C07K14/725 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/30 , A61K38/00 , A61K39/00
CPC分类号： C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K14/71 , C07K16/2863 , C07K16/30 , A61K38/00 , A61K2039/505 , A61K2039/5156 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/03 , C07K2319/30 , C07K2319/50 , C07K2319/70
摘要： The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family α-receptor 4 (GFRα4).
-
公开(公告)号：US20230295296A1
公开(公告)日：2023-09-21
申请号：US18162236
申请日：2023-01-31
发明人： Felipe Bedoya , Saba Ghassemi , Carl H. June , Bruce L. Levine , Jan J. Melenhorst , Michael C. Milone , Daniel J. Powell, Jr. , Zoe Zheng
IPC分类号： C07K16/28 , C12N9/12 , C07K14/705 , C07K14/725 , C12N5/0783 , A61K35/17 , C12N5/00
CPC分类号： C07K16/2803 , C12N9/1276 , C07K14/70517 , C07K14/7051 , C07K14/70578 , C07K16/28 , C12N5/0636 , A61K35/17 , C12N5/0087 , C12N5/0638 , C12Y207/07049 , C07K2317/622 , C07K2319/74 , C07K2319/03 , C12N2510/00 , C07K2317/14 , A61K2039/5156
摘要： The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
-
公开(公告)号：US11591404B2
公开(公告)日：2023-02-28
申请号：US16884867
申请日：2020-05-27
发明人： Jennifer Brogdon , Saar Gill , David Jonathan Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
IPC分类号： C07K16/28 , C07K16/24 , C12N5/0783 , A61K39/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
-
公开(公告)号：US20210087279A1
公开(公告)日：2021-03-25
申请号：US16941148
申请日：2020-07-28
发明人： Boris Engels , Andreas Loew , Michael C. Milone , Li Zhou
IPC分类号： C07K16/28 , C07K14/725 , A61K38/00 , C07K14/705 , C07K16/00 , A61K39/00 , A61K38/17 , A61K39/395 , C12N15/62
摘要： Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
公开(公告)号：US20210079059A1
公开(公告)日：2021-03-18
申请号：US17078903
申请日：2020-10-23
IPC分类号： C07K14/725 , C07K14/705 , C07K16/28 , C07K16/30 , C07K14/71
摘要： The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family α-receptor 4 (GFRα4).
-
公开(公告)号：US20200283729A1
公开(公告)日：2020-09-10
申请号：US16599988
申请日：2019-10-11
IPC分类号： C12N5/0783 , A61K39/00 , C07K16/32 , A61K39/395 , C07K16/28 , A61K39/39 , C07K16/30
摘要： The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
-
公开(公告)号：US10577417B2
公开(公告)日：2020-03-03
申请号：US15511973
申请日：2015-09-17
发明人： Gregory Beatty , Boris Engels , Neeraja Idamakanti , Carl H. June , Andreas Loew , Michael C. Milone , Huijuan Song , Enxiu Wang , Qilong Wu
IPC分类号： A61K35/17 , C07K14/705 , C07K16/28 , C07K16/30 , C07K14/725 , C07K14/74 , C12N5/0783
摘要： The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
-
公开(公告)号：US20240343783A1
公开(公告)日：2024-10-17
申请号：US18420525
申请日：2024-01-23
发明人： Michael C. Milone , Enxiu Wang
IPC分类号： C07K16/18 , C07K14/705 , C07K14/735
CPC分类号： C07K16/18 , C07K14/70503 , C07K14/70535 , C07K2319/03 , C07K2319/33 , C07K2319/70
摘要： The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
-
公开(公告)号：US11970525B2
公开(公告)日：2024-04-30
申请号：US17078903
申请日：2020-10-23
IPC分类号： C07K14/725 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/30 , A61K38/00 , A61K39/00
CPC分类号： C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K14/71 , C07K16/2863 , C07K16/30 , A61K38/00 , A61K2039/505 , A61K2039/5156 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/03 , C07K2319/30 , C07K2319/50 , C07K2319/70
摘要： The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family α-receptor 4 (GFRα4).
-
公开(公告)号：US20230071283A1
公开(公告)日：2023-03-09
申请号：US16093758
申请日：2017-04-14
申请人： Andrei Golosov , Carla Patricia Pinto Guimaraes , Gregory Motz , Michael C. Milone , Christoph T. Ellebrecht , Aimee S. Payne , Novartis AG , The Trustees of the University of Pennsylvania
发明人： Andrei Golosov , Carla Patricia Pinto Guimaraes , Gregory Motz , Michael C. Milone , Christoph T. Ellebrecht , Aimee S. Payne
IPC分类号： C07K14/725
摘要： Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential elements: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the two. Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is selectively ablated in a subject after adoptive transfer. Pharmaceutical compositions comprising the temporally regulated CAR modified T cell are also described herein.
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.038 秒)
